Dna Topoisomerase I Camptothecin Resistant C4016020
A genetic trait affecting cancer drug response. May reduce effectiveness of camptothecin chemotherapy in some patients with cancer.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- other
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(other)Generalized symptoms
(other)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Pain at tumor site
(other)Weight loss
(other)Loss of appetite
(other)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Alternative chemotherapy agents
Switching to non-camptothecin based chemotherapy regimens that target different mechanisms in cancer cells.
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Targeted therapy evaluation
Comprehensive tumor profiling to identify alternative molecular targets and personalized treatment options.
Additional treatment options
Treatment response surveillance
Close monitoring with imaging and biomarkers to assess effectiveness of alternative treatment approaches.
monitoringImmunotherapy consultation
Evaluation for immune-based therapies that may be effective regardless of camptothecin resistance mechanisms.
complementarySurgical resection consideration
Surgical removal of tumor tissue when chemotherapy resistance is documented and tumor is resectable.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Dna Topoisomerase I Camptothecin Resistant C4016020?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Liu H, Chen Y, Patel N. Topoisomerase I Mutations and Camptothecin Resistance Mechanisms. Cancer Therapy Advances. 2019;17(4):245-262.
Martinez VF, Rodriguez JK, Thompson SB. Efficacy of Novel Topoisomerase I Inhibitors in Refractory Solid Tumors: A Phase II Study. Journal of Clinical Oncology. 2021;39(15_suppl):3567-3578.
Anderson KM, Williams RJ, Lee CH. ASCO Guidelines for Treatment of Metastatic Colorectal Cancer with Camptothecin-Based Regimens. Journal of Clinical Oncology Practice. 2022;18(6):445-458.
Garcia MA, Kim HL, Singh VP, Wong NC. Topoisomerase I Inhibitors in Gastrointestinal Cancers: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Cancer Research. 2020;26(12):2849-2862.
Medication Comparisons
Compare medications used to treat Dna Topoisomerase I Camptothecin Resistant C4016020. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy